ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company developing treatments for mental health disorders. Its lead compounds include PCN-101, a subcutaneous R-ketamine for treatment-resistant depression; RL-007, a modulator for cognitive impairment in schizophrenia; DMX-1002, an oral ibogaine for opioid use disorder; GRX-917, an oral deuterated etifoxine for generalized anxiety disorder; and NN-101, an intranasal N-acetylcysteine for mild traumatic brain injuries. Other candidates include VLS-01 for depression and EMP-01 for PTSD. We show 16 historical shares outstanding datapoints in our ATAI shares outstanding history coverage, used to compute ATAI market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ATAI market cap history over the course of time is important for investors
interested in comparing ATAI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ATAI versus a peer is one thing; comparing
ATAI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ATAI can fluctuate over the course of history.
With this page we aim to empower investors researching ATAI by allowing them to research the ATAI market cap history. |
Free ATAI Email Alerts:
Video: The Importance of Market Cap
